|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Characteristics and prognosis of CRC with NRAS mutations are different from those with KRAS or BRAF mutations.
|
24806883 |
2014 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have demonstrated that, in advanced colorectal carcinoma (CRC) patients, extended RAS (in KRAS exons 2-4 and NRAS exons 2-4) and BRAF mutations are negative predictors for anti-EGFR treatment efficacy and negative prognostic factor, respectively.
|
25262986 |
2014 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The Japanese Society of Medical Oncology (JSMO) previously published 2 editions of the clinical guidelines: "Japanese guidelines for testing of KRAS gene mutation in colorectal cancer" in 2008 and "Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients" in 2014.
|
29873882 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation.
|
31185985 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue.
|
31207216 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Testing for NRAS mutation at codon Q61 is of therapeutic, prognostic, and diagnostic importance for metastatic melanoma, thyroid carcinoma, and colorectal carcinoma.
|
26712868 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We found "rare mutations" in RAS genes in nearly 14% of CRCs-i.e., in almost a quarter (24.0%) of KRAS exon 2 wild type CRCs, including 2.3% in KRAS exon 3, 8.2% in KRAS exon 4 and 3.4% in NRAS.
|
29666387 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
- To evaluate the significance of NRAS Q61R mutant-specific immunohistochemistry in a cohort of colorectal carcinomas.
|
28353383 |
2017 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Four of the polymorphisms exhibited an increased colorectal cancer risk [GSTT1, NAT2 (phenotype), HRAS1, and ALDH2].
|
12433710 |
2002 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Colorectal carcinomas (CRCs) are sensitive to treatment by anti-epidermal growth factor receptor (EGFR) antibodies only if they do not carry activating mutations in down-stream EGFR targets (KRAS/NRAS/BRAF).
|
29470838 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The clinicopathologic features and frequency of KRAS mutations in colorectal cancer (CRC) patients have been reported; however, the characteristics and impact of NRAS and HRAS mutations on the survival of CRC patients have seldom been addressed.
|
27394063 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
NRAS-mutation(+) CRC preferentially occurred in elder patients (P = 0.02) and at the distal colon (P = 0.006), showed significantly less lymph vessel invasion (P = 0.002), and correlated with LME (P = 8 × 10<sup>-5</sup> ).
|
28378457 |
2017 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In advanced colorectal carcinoma (CRC) patients, extended RAS mutations testing (KRAS exons 2 to 4 and NRAS exons 2 to 4) is a prerequisite for patient stratification to anti-EGFr therapy.
|
26163758 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Although the presence of HER2 amplifications and oncogenic mutations in KRAS, NRAS, and BRAF are associated with EGFR-targeted therapy resistance, for a large population of CRC patients the underlying mechanism of RAS-MEK-ERK hyperactivation is not clear.
|
30858928 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Two-hundred and forty-two formalin-fixed paraffin-embedded (FFPE) human malignant colorectal cancer (CRC) tissue samples were identified in departmental archives and tested with both the Idylla NRAS-BRAF mutation test and the Agena Bioscience MassARRAY test.
|
28899979 |
2018 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that colorectal carcinomas with either K-ras mutations or altered forms of N-ras protein may increase their tumorigenic potential via the induction of cathepsin L or B expression levels.
|
9699522 |
1998 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
NRAS mutations occur in 3-5% of colorectal cancer.
|
24806288 |
2015 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer.
|
31589789 |
2020 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In the multivariate setting, left-sided CRC only turned out as a significant positive prognostic parameter regarding progression-free survival, irrespective of the type of chemotherapy or BRAF and NRAS mutations.
|
30711966 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.
|
21305640 |
2011 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
As a group, CRC complicating Crohn's colitis is BRAF (97 %) and NRAS (100 %) wild type and the vast majority is microsatellite stable (94 %); KRAS-mutations were found in six cases (18 %).
|
27026089 |
2016 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
|
28560458 |
2017 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Activating oncogenic mutations in KRAS and NRAS are common in CRC, driving tumor progression and influencing efficacy of both cytotoxic and targeted therapies.
|
31427573 |
2019 |
|
Colorectal Carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Approximately 2-6% of colorectal cancers harbor NRAS mutations.
|
23400451 |
2013 |